Fairmount Funds Management LLC — 13F Holdings & Portfolio
CIK 1802528 · latest 13F-HR filed 2026-08-14
Fairmount Funds Management LLC manages $1.51B in 13F-reported U.S. long-equity assets across 12 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ORKA (23.31%), DNTH (16.35%), DMRA (14.98%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position, exited 1, added to 8, and trimmed 0.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
SUITE 400
WEST CONSHOHOCKEN, PA 19428
$1.51B
Long-equity book
12
Distinct positions
2026-06-30
Filed 2026-08-14
+1 / −1 / ↑8 / ↓0
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ORUKA THERAPEUTICS INC$170.9M +94.0%
- JADE BIOSCIENCES INC$37.2M +58.1%
- DIANTHUS THERAPEUTICS INC$34.4M +16.2%
- ENLIVEN THERAPEUTICS INC$21.4M +29.5%
- VIRIDIAN THERAPEUTICS INC$17.0M +22.1%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $352.6M | 23.31% | 3,705,262 | SH |
| 2 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $247.3M | 16.35% | 2,537,191 | SH |
| 3 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $226.6M | 14.98% | 8,713,000 | SH |
| 4 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $213.0M | 14.08% | 5,503,418 | SH |
| 5 | JADE BIOSCIENCES INC | JBIO | 008064206 | $101.2M | 6.69% | 4,553,494 | SH |
| 6 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $94.2M | 6.22% | 1,855,644 | SH |
| 7 | VIRIDIAN THERAPEUTICS INC | VRDN | 92790C104 | $93.5M | 6.18% | 5,090,928 | SH |
| 8 | ZENAS BIOPHARMA INC | ZBIO | 98937L105 | $59.9M | 3.96% | 2,359,025 | SH |
| 9 | CRESCENT BIOPHARMA INC. | CBIO | G2545C104 | $49.5M | 3.27% | 2,747,866 | SH |
| 10 | APOGEE THERAPEUTICS INC | APGE | 03770N101 | $39.6M | 2.62% | 298,647 | SH |
| 11 | FAETH THERAPEUTICS INC | FTH | 81728A207 | $18.1M | 1.19% | 722,020 | SH |
| 12 | INHIBIKASE THERAPEUTICS INC | IKT | 45719W205 | $17.5M | 1.16% | 8,625,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $1.51B | 12 | 0001104659-26-096405 |
| 2026-03-31 | 2026-05-15 | $1.38B | 12 | 0001104659-26-062419 |
| 2025-12-31 | 2026-02-17 | $1.31B | 13 | 0001104659-26-016303 |
| 2025-09-30 | 2025-11-14 | $1.11B | 17 | 0001104659-25-112427 |